Gvoke Hypopen is owned by Xeris.
Gvoke Hypopen contains Glucagon.
Gvoke Hypopen has a total of 1 drug patent out of which 0 drug patents have expired.
Gvoke Hypopen was authorised for market use on 10 September, 2019.
Gvoke Hypopen is available in solution;subcutaneous dosage forms.
Gvoke Hypopen can be used as treatment of severe hypoglycemia.
The generics of Gvoke Hypopen are possible to be released after 22 April, 2036.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9649364||XERIS||Methods for producing stable therapeutic formulations in aprotic polar solvents|| |
(13 years from now)
|New Product (NP)||Sep 10, 2022|
Market Authorisation Date: 10 September, 2019
Treatment: Treatment of severe hypoglycemia
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic